-
Innovation Ranking
NewInnovation Ranking – X4 Pharmaceuticals Inc
X4 Pharmaceuticals Inc, formerly Arsanis Inc, is a clinical stage bio pharmaceutical company that develops oral, small molecule therapeutics to treat cancer and rare diseases. The company’s pipeline products include Mavorixafor, an allosteric inhibitor of CXCR4 for the treatment of Warts, Hypogammaglobulinemia, Immunodeficiency and Myelokathexis (WHIM) syndrome X4P-002 and X4P-003, small molecule antagonists of chemokine receptor CXCR4 for treating glioblastoma multiforme and primary immune deficiencies (PI's). The company is developing oral allosteric antagonists of CXCR4 in order to block overstimulation...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mavorixafor in WHIM Syndrome (Warts, Hypogammaglobulinemia, Infections and Myelokathexis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mavorixafor in WHIM Syndrome (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mavorixafor in WHIM Syndrome (Warts, Hypogammaglobulinemia, Infections...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mavorixafor in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mavorixafor in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mavorixafor in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: Mavorixafor (X4P-001)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EP-547 in Uremic (Renal) Pruritus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EP-547 in Uremic (Renal) Pruritus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EP-547 in Uremic (Renal) Pruritus Drug Details: EP-547 is under developmant...
-
Product Insights
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) - Drugs In Development, 2023’, provides an overview of the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leukocyte Disorders (White Blood Cell Disorders) - Drugs In Development, 2023’, provides an overview of the Leukocyte Disorders (White Blood Cell Disorders) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leukocyte Disorders (White Blood Cell Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Primary Immune Deficiency (PID) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Immune Deficiency (PID) - Drugs In Development, 2023’, provides an overview of the Primary Immune Deficiency (PID) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2023’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Streptococcal Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Streptococcal Pneumonia - Drugs In Development, 2023’, provides an overview of the Streptococcal Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...